Cardiovascular Events for a Long Time End of COVID 19 Infection (LONGCOVIDWP3)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Active, not recruiting

Conditions: Myocardial Disease

Treatments: Other: Sample blood

Study type: Observational

Funder types: Other

Identifiers

NCT05729152

5031

Details and patient eligibility

About

In the follow-up of partecipants with Covid-19 infection, persistence of cardiovascular symptoms is common. Studies on the acute phase of Covid-19 infection have demonstrated a significant prevalence of acute myocardial damage (15-44%), and imaging studies have confirmed the presence of structural changes in the pericardium and myocardium several months after the acute phase. The aim of the project is to identify the prevalence and characteristics of long-term cardiovascular changes in Covid-19 infection.

Full description

The study is a continuation of the "CARDICoVRISK" registry project ("Cardiovascular risk and effects ancillary effects of cardiology drug therapy during n-CoV-19 infection"), which collected data on alterations cardiovascular changes during the acute phase and shortly after the acute phase.

The design of the current study is observational cross-sectional comparison with historical data. The study plans to enroll 240 patients hospitalized during the acute phase of COVID-19 infection. Enrollment of patients will be carried out in three separate centers. Enrolled patients will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram.

Enrollment: 240 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• partecipants with previous hospitalization for Covid-19 infection confirmed by pharyngeal molecular swab at least 12 months prior to enrollment;
• adult partecipants between the ages of 18 and 90 years old;
• signature of informed consent;

Exclusion criteria

• partecipants with poor echocardiographic acoustic window impairing the performance of the examination
• partecipants with atrial fibrillation
• partecipants with ischemic or nonischemic heart disease with known decreased systolic function of the left ventricle left